Abogen is a China-based clinical-stage biotechnology company advancing mRNA-based therapeutics for the treatment of cancer and infectious diseases, including COVID-19.
Location: China
Employees: 11-50
Founded date: 2019
Investors 8
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
| - | Avenue Par... | avenue-par... |
| 23.02.2022 | 5Y Capital | 5ycap.com |
| - | Qiming Ven... | qimingvent... |
| 10.07.2026 | Magic Ston... | msacap.com |
| - | YF Capital | yfc.cn |
| 24.08.2021 | Qiming Ven... | qimingvc.c... |
| 13.10.2022 | IMO Ventur... | imo.vc/ |
Mentions in press and media 3
| Date | Title | Description |
| 23.08.2024 | Abogen announced development of Cis-System-based circular RNAs | SUZHOU, China, Aug. 23, 2024 /PRNewswire/ -- Abogen Biosciences ("Abogen" or the "Company") announced a publication titled "Efficient circularization of protein-encoding RNAs via a novel cis-splicing system " i... |
| 18.04.2022 | Biotech's top 10 money raisers of 2021 | After a bustling, record-setting 2020 for private biotechs raising cash, the bar heading into 2021 was exceptionally high. Turns out, private investors elected to just take the bar and do pull-ups, breaking 2020’s record by a whopping 26%. ... |
| 30.11.2021 | China’s Abogen Biosciences raises $300m in Series C+ round | Chinese mRNA vaccine developer Suzhou Abogen Biosciences Co Ltd has raised as much as $300 million in its Series C+ round of funding, per an announcement. SoftBank Vision Fund alongside returning investor 5Y Capital jointly led the funding.... |